share_log

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A：證券上市註冊聲明(修正)
美股sec公告 ·  05/06 19:53
牛牛AI助理已提取核心訊息
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 Registration Statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment pertains to a proposed public offering of securities, including up to 3,322,259 shares of common stock, Pre-Funded Warrants to purchase an equivalent number of shares, and Series B-1 and B-2 Common Warrants to purchase up to 3,322,259 shares of common stock each. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities or proceeds required for closing. The securities may be sold to purchasers whose ownership would exceed 4.99% of outstanding common stock, in the form of Pre-Funded Warrants...Show More
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 Registration Statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment pertains to a proposed public offering of securities, including up to 3,322,259 shares of common stock, Pre-Funded Warrants to purchase an equivalent number of shares, and Series B-1 and B-2 Common Warrants to purchase up to 3,322,259 shares of common stock each. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities or proceeds required for closing. The securities may be sold to purchasers whose ownership would exceed 4.99% of outstanding common stock, in the form of Pre-Funded Warrants, to avoid exceeding the ownership threshold. The offering is expected to close no later than May 15, 2024, with T2 Biosystems' common stock listed on the Nasdaq Capital Market under the symbol 'TTOO.' The closing price of T2 Biosystems' common stock on Nasdaq as of May 1, 2024, was $3.01 per share. The company intends to use the net proceeds for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs.
T2 Biosystems, Inc. 是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月6日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明修正案。該修正案涉及證券的擬議公開發行，包括最多3,322,259股普通股、用於購買等量股票的預籌認股權證，以及每份購買最多3,322,259股普通股的B-1和B-2系列普通認股權證。此次發行以 “合理的最大努力” 爲基礎，不要求最低數量的證券或收益即可完成。證券可以以預先注資認股權證的形式出售給所有權超過已發行普通股4.99％的購買者，以避免超過所有權門檻。此次發行預計不遲於2024年5月15日結束，T2 Biosystems的普通股在納斯達克資本市場上市，股票代碼爲 “TTOO”。截至2024年5月1日，T2 Biosystems在納斯達克的普通股的收盤價爲每股3.01美元。該公司打算將淨收益用於營運資金和一般公司用途，包括銷售和營銷、製造和臨床開發成本。
T2 Biosystems, Inc. 是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月6日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明修正案。該修正案涉及證券的擬議公開發行，包括最多3,322,259股普通股、用於購買等量股票的預籌認股權證，以及每份購買最多3,322,259股普通股的B-1和B-2系列普通認股權證。此次發行以 “合理的最大努力” 爲基礎，不要求最低數量的證券或收益即可完成。證券可以以預先注資認股權證的形式出售給所有權超過已發行普通股4.99％的購買者，以避免超過所有權門檻。此次發行預計不遲於2024年5月15日結束，T2 Biosystems的普通股在納斯達克資本市場上市，股票代碼爲 “TTOO”。截至2024年5月1日，T2 Biosystems在納斯達克的普通股的收盤價爲每股3.01美元。該公司打算將淨收益用於營運資金和一般公司用途，包括銷售和營銷、製造和臨床開發成本。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。